Deluxe apartment in the sky.

It doesn’t get much better for Big Pharma than a win in early-stage breast cancer. Merck announced last week that adding pembro to neoadjuvant chemo for early-stage triple negative breast cancer improved not only pathologic complete response rate but also event free survival in its phase 3 KEYNOTE-522 trial. | Merck 2021